Skip to main content
. 2021 Jun 22;22:184. doi: 10.1186/s12931-021-01767-z

Fig. 3.

Fig. 3

Efficacy of mepolizumab, by allergen sensitivity. A Change from baseline to study end in pre-bronchodilator FEV1 per season; B Change from baseline to study end in SGRQ total score per season; C Change from baseline to study end in ACQ-5 score per season. All plots are for patients receiving mepolizumab versus placebo. ACQ Asthma Control Questionnaire, CI confidence interval, FEV1 forced expiratory volume in 1 s, SGRQ St George’s Respiratory Questionnaire